Replies to post #185948 on Biotech Values

[DewDiligence]

Roche—It’s curious that the commercial rights to OP0595 were already split between two companies:

Roche, Meiji Seika Pharma, and Fedora announced today that they have entered into a license agreement for the development and commercialization of OP0595, a beta-lactamase inhibitor in phase I clinical development. Under the agreement, Roche obtains worldwide rights from both companies for development and commercialization with the exception of Japan, where Meiji will retain sole commercialization rights.